Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.

[1]  Zhiyun Xu,et al.  Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial , 2018, JAMA.

[2]  J. Alexander.  Ticagrelor Following Coronary Artery Bypass Grafting: For Better Vein Graft Patency or Better Patient Outcomes? , 2018, JAMA.

[3]  C. Chartrand-Lefebvre,et al.  Off-pump Versus On-pump Coronary Artery Bypass Surgery: Graft Patency Assessment With Coronary Computed Tomographic Angiography A Prospective Multicenter Randomized Controlled Pilot Study , 2017, Journal of thoracic imaging.

[4]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[5]  Deepak L. Bhatt,et al.  Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. , 2017, The Canadian journal of cardiology.

[6]  D. Likosky,et al.  Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. , 2017, The New England journal of medicine.

[7]  S. Yusuf,et al.  Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. , 2013, The New England journal of medicine.

[8]  S. Yusuf,et al.  Off-pump or on-pump coronary-artery bypass grafting. , 2012, The New England journal of medicine.

[9]  S. Yusuf,et al.  Off-pump or on-pump coronary-artery bypass grafting at 30 days. , 2012, The New England journal of medicine.

[10]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[11]  A. Shroyer,et al.  On-pump versus off-pump coronary-artery bypass surgery. , 2009, The New England journal of medicine.

[12]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[13]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[14]  Prevent Iv Investigators.  Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. , 2005 .

[15]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[16]  Deepak L. Bhatt,et al.  Superiority of Clopidogrel Versus Aspirin in Patients With Prior Cardiac Surgery , 2001, Circulation.

[17]  B. Hoogwerf,et al.  Long-Term Effects on Clinical Outcomes of Aggressive Lowering of Low-Density Lipoprotein Cholesterol Levels and Low-Dose Anticoagulation in the Post Coronary Artery Bypass Graft Trial , 2000 .

[18]  Post Coronary Artery Bypass Graft Trial Investigators.  The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.

[19]  T. Chalmers,et al.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration , 1994, The Lancet.

[20]  B. Pasche,et al.  The platelet function defect of cardiopulmonary bypass. , 1993, Blood.

[21]  J. Burton,et al.  Coronary Bypass Graft Fate: Angiographic Grading of 1400 Consecutive Grafts Early after Operation and of 1132 after One Year , 1978, Circulation.

[22]  S. Yusuf,et al.  Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. , 2016, The New England journal of medicine.

[23]  B. Hoogwerf,et al.  Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. , 2000, Circulation.